NO327854B1 - DNA-sekvens, replikerbar ekspresjonsvektor, transformert eukaryot eller prokaryot vertscelle; RAP-2 protein, isoform, fragment, funksjonell analog eller derivater derav samt fremgangsmate for fremstilling og anvendelse derav; farmasoytisk preparat, anvendelse av en rekombinant dyrevirusvektor og en vektor kodende for ribozym sekvens. - Google Patents

DNA-sekvens, replikerbar ekspresjonsvektor, transformert eukaryot eller prokaryot vertscelle; RAP-2 protein, isoform, fragment, funksjonell analog eller derivater derav samt fremgangsmate for fremstilling og anvendelse derav; farmasoytisk preparat, anvendelse av en rekombinant dyrevirusvektor og en vektor kodende for ribozym sekvens. Download PDF

Info

Publication number: NO327854B1
Authority: NO; Norway
Prior art keywords: rap; protein; sequence; cell; rip
Prior art date: 1998-03-19

Application number

NO20004649A

Other languages

English (en)

Norwegian (no)

Other versions

NO20004649D0 (no

NO20004649L (no

Inventor

David Wallach

Andrei Kovalenko

Marshall S Horwitz

Yongan Li

Original Assignee

Yeda Res & Dev

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-03-19

Filing date

2000-09-18

Publication date

2009-10-05

1998-03-19 Priority claimed from IL12375898A external-priority patent/IL123758A0/xx

2000-09-18 Application filed by Yeda Res & Dev filed Critical Yeda Res & Dev

2000-09-18 Publication of NO20004649D0 publication Critical patent/NO20004649D0/no

2000-10-30 Publication of NO20004649L publication Critical patent/NO20004649L/no

2009-10-05 Publication of NO327854B1 publication Critical patent/NO327854B1/no

Links

108090000623 proteins and genes Proteins 0.000 title claims abstract description 367
102000004169 proteins and genes Human genes 0.000 title claims abstract description 347
238000000034 method Methods 0.000 title claims abstract description 79
239000012634 fragment Substances 0.000 title claims description 95
108010029485 Protein Isoforms Proteins 0.000 title claims description 49
102000001708 Protein Isoforms Human genes 0.000 title claims description 49
108091028043 Nucleic acid sequence Proteins 0.000 title claims description 48
239000013598 vector Substances 0.000 title claims description 39
239000013604 expression vector Substances 0.000 title claims description 19
108090000994 Catalytic RNA Proteins 0.000 title claims description 17
102000053642 Catalytic RNA Human genes 0.000 title claims description 17
241000700605 Viruses Species 0.000 title claims description 17
108091092562 ribozyme Proteins 0.000 title claims description 17
241001465754 Metazoa Species 0.000 title claims description 16
238000002360 preparation method Methods 0.000 title claims description 12
239000008194 pharmaceutical composition Substances 0.000 title 1
230000000694 effects Effects 0.000 claims abstract description 116
230000003834 intracellular effect Effects 0.000 claims abstract description 41
206010061218 Inflammation Diseases 0.000 claims abstract description 38
230000004054 inflammatory process Effects 0.000 claims abstract description 38
238000004519 manufacturing process Methods 0.000 claims abstract description 31
210000004027 cell Anatomy 0.000 claims description 194
230000027455 binding Effects 0.000 claims description 103
238000009739 binding Methods 0.000 claims description 102
108090000765 processed proteins & peptides Proteins 0.000 claims description 52
230000030833 cell death Effects 0.000 claims description 47
230000004083 survival effect Effects 0.000 claims description 47
230000001404 mediated effect Effects 0.000 claims description 34
230000014509 gene expression Effects 0.000 claims description 30
230000005764 inhibitory process Effects 0.000 claims description 17
238000002955 isolation Methods 0.000 claims description 15
239000000825 pharmaceutical preparation Substances 0.000 claims description 15
230000000692 anti-sense effect Effects 0.000 claims description 14
230000008569 process Effects 0.000 claims description 14
238000011282 treatment Methods 0.000 claims description 14
108091034117 Oligonucleotide Proteins 0.000 claims description 12
230000001413 cellular effect Effects 0.000 claims description 12
108020004999 messenger RNA Proteins 0.000 claims description 12
210000004881 tumor cell Anatomy 0.000 claims description 8
-1 analogues Proteins 0.000 claims description 7
102000000844 Cell Surface Receptors Human genes 0.000 claims description 6
108010001857 Cell Surface Receptors Proteins 0.000 claims description 6
206010028980 Neoplasm Diseases 0.000 claims description 6
230000002068 genetic effect Effects 0.000 claims description 5
239000000203 mixture Substances 0.000 claims description 5
208000023275 Autoimmune disease Diseases 0.000 claims description 4
102000018697 Membrane Proteins Human genes 0.000 claims description 4
108010052285 Membrane Proteins Proteins 0.000 claims description 4
206010040070 Septic Shock Diseases 0.000 claims description 4
208000006454 hepatitis Diseases 0.000 claims description 4
230000036303 septic shock Effects 0.000 claims description 4
239000003937 drug carrier Substances 0.000 claims description 3
238000003780 insertion Methods 0.000 claims description 3
230000037431 insertion Effects 0.000 claims description 3
231100000283 hepatitis Toxicity 0.000 claims description 2
230000002147 killing effect Effects 0.000 claims description 2
230000004481 post-translational protein modification Effects 0.000 claims description 2
108020001775 protein parts Proteins 0.000 claims description 2
230000003612 virological effect Effects 0.000 claims description 2
102100029276 Protein RD3 Human genes 0.000 claims 1
230000004654 survival pathway Effects 0.000 abstract description 6
108090000829 Ribosome Inactivating Proteins Proteins 0.000 abstract description 3
230000006721 cell death pathway Effects 0.000 abstract description 2
102100022419 RPA-interacting protein Human genes 0.000 abstract 1
235000018102 proteins Nutrition 0.000 description 319
108060008682 Tumor Necrosis Factor Proteins 0.000 description 70
102100040247 Tumor necrosis factor Human genes 0.000 description 68
108010052621 fas Receptor Proteins 0.000 description 66
102000018823 fas Receptor Human genes 0.000 description 65
102000003945 NF-kappa B Human genes 0.000 description 56
108010057466 NF-kappa B Proteins 0.000 description 56
102000005962 receptors Human genes 0.000 description 54
108020003175 receptors Proteins 0.000 description 54
235000001014 amino acid Nutrition 0.000 description 47
150000001413 amino acids Chemical class 0.000 description 43
230000003993 interaction Effects 0.000 description 43
230000037361 pathway Effects 0.000 description 42
102000004196 processed proteins & peptides Human genes 0.000 description 40
238000006243 chemical reaction Methods 0.000 description 39
102100023132 Transcription factor Jun Human genes 0.000 description 35
102100028194 Mitogen-activated protein kinase kinase kinase kinase 4 Human genes 0.000 description 32
108040008091 NF-kappaB-inducing kinase activity proteins Proteins 0.000 description 32
102000010170 Death domains Human genes 0.000 description 31
108050001718 Death domains Proteins 0.000 description 31
230000004913 activation Effects 0.000 description 31
101001050288 Homo sapiens Transcription factor Jun Proteins 0.000 description 29
108020004635 Complementary DNA Proteins 0.000 description 28
102100033732 Tumor necrosis factor receptor superfamily member 1A Human genes 0.000 description 27
230000006870 function Effects 0.000 description 27
238000004458 analytical method Methods 0.000 description 26
238000010804 cDNA synthesis Methods 0.000 description 26
239000002299 complementary DNA Substances 0.000 description 26
108020004414 DNA Proteins 0.000 description 25
108090000925 TNF receptor-associated factor 2 Proteins 0.000 description 24
102100034779 TRAF family member-associated NF-kappa-B activator Human genes 0.000 description 24
230000006698 induction Effects 0.000 description 21
229920001184 polypeptide Polymers 0.000 description 21
238000006467 substitution reaction Methods 0.000 description 21
239000000427 antigen Substances 0.000 description 20
102000014914 Carrier Proteins Human genes 0.000 description 19
102000004091 Caspase-8 Human genes 0.000 description 19
102100022893 Histone acetyltransferase KAT5 Human genes 0.000 description 19
101710116149 Histone acetyltransferase KAT5 Proteins 0.000 description 19
108091008324 binding proteins Proteins 0.000 description 19
238000012217 deletion Methods 0.000 description 19
230000037430 deletion Effects 0.000 description 19
239000003446 ligand Substances 0.000 description 19
108090000538 Caspase-8 Proteins 0.000 description 18
102000035195 Peptidases Human genes 0.000 description 18
108091005804 Peptidases Proteins 0.000 description 18
239000004365 Protease Substances 0.000 description 18
108091007433 antigens Proteins 0.000 description 18
102000036639 antigens Human genes 0.000 description 18
230000003013 cytotoxicity Effects 0.000 description 18
231100000135 cytotoxicity Toxicity 0.000 description 18
241000699666 Mus <mouse, genus> Species 0.000 description 17
238000010396 two-hybrid screening Methods 0.000 description 16
238000003556 assay Methods 0.000 description 15
230000015572 biosynthetic process Effects 0.000 description 15
230000004044 response Effects 0.000 description 15
239000007787 solid Substances 0.000 description 15
102000004190 Enzymes Human genes 0.000 description 14
108090000790 Enzymes Proteins 0.000 description 14
229940088598 enzyme Drugs 0.000 description 14
239000003112 inhibitor Substances 0.000 description 14
230000002018 overexpression Effects 0.000 description 14
108091000080 Phosphotransferase Proteins 0.000 description 13
125000000539 amino acid group Chemical group 0.000 description 13
238000013459 approach Methods 0.000 description 13
230000004068 intracellular signaling Effects 0.000 description 13
102000020233 phosphotransferase Human genes 0.000 description 13
238000003752 polymerase chain reaction Methods 0.000 description 13
230000011664 signaling Effects 0.000 description 13
101000801228 Homo sapiens Tumor necrosis factor receptor superfamily member 1A Proteins 0.000 description 12
102100031822 Optineurin Human genes 0.000 description 12
230000004071 biological effect Effects 0.000 description 12
238000001514 detection method Methods 0.000 description 12
239000000523 sample Substances 0.000 description 12
240000004808 Saccharomyces cerevisiae Species 0.000 description 11
238000010367 cloning Methods 0.000 description 11
150000001875 compounds Chemical class 0.000 description 11
230000001472 cytotoxic effect Effects 0.000 description 11
238000002474 experimental method Methods 0.000 description 11
238000000338 in vitro Methods 0.000 description 11
101710131459 Optineurin Proteins 0.000 description 10
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 10
230000002401 inhibitory effect Effects 0.000 description 10
230000026731 phosphorylation Effects 0.000 description 10
238000006366 phosphorylation reaction Methods 0.000 description 10
230000001105 regulatory effect Effects 0.000 description 10
210000001519 tissue Anatomy 0.000 description 10
238000013518 transcription Methods 0.000 description 10
230000035897 transcription Effects 0.000 description 10
241000699670 Mus sp. Species 0.000 description 9
230000009471 action Effects 0.000 description 9
125000003275 alpha amino acid group Chemical group 0.000 description 9
230000006907 apoptotic process Effects 0.000 description 9
238000012512 characterization method Methods 0.000 description 9
201000010099 disease Diseases 0.000 description 9
210000004408 hybridoma Anatomy 0.000 description 9
239000013612 plasmid Substances 0.000 description 9
238000010561 standard procedure Methods 0.000 description 9
108091032973 (ribonucleotides)n+m Proteins 0.000 description 8
108060001084 Luciferase Proteins 0.000 description 8
230000003321 amplification Effects 0.000 description 8
239000003795 chemical substances by application Substances 0.000 description 8
229940079593 drug Drugs 0.000 description 8
239000003814 drug Substances 0.000 description 8
230000002255 enzymatic effect Effects 0.000 description 8
230000001965 increasing effect Effects 0.000 description 8
238000011534 incubation Methods 0.000 description 8
239000012528 membrane Substances 0.000 description 8
238000003199 nucleic acid amplification method Methods 0.000 description 8
239000002773 nucleotide Substances 0.000 description 8
125000003729 nucleotide group Chemical group 0.000 description 8
238000002741 site-directed mutagenesis Methods 0.000 description 8
239000007790 solid phase Substances 0.000 description 8
239000000758 substrate Substances 0.000 description 8
238000001262 western blot Methods 0.000 description 8
239000005089 Luciferase Substances 0.000 description 7
108700026244 Open Reading Frames Proteins 0.000 description 7
108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 description 7
231100000433 cytotoxic Toxicity 0.000 description 7
230000006951 hyperphosphorylation Effects 0.000 description 7
210000004962 mammalian cell Anatomy 0.000 description 7
230000004048 modification Effects 0.000 description 7
238000012986 modification Methods 0.000 description 7
230000035772 mutation Effects 0.000 description 7
230000019491 signal transduction Effects 0.000 description 7
239000000243 solution Substances 0.000 description 7
230000000638 stimulation Effects 0.000 description 7
102000003298 tumor necrosis factor receptor Human genes 0.000 description 7
YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 6
MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 6
108091026890 Coding region Proteins 0.000 description 6
101150064015 FAS gene Proteins 0.000 description 6
102000003893 Histone acetyltransferases Human genes 0.000 description 6
108090000246 Histone acetyltransferases Proteins 0.000 description 6
101001043754 Homo sapiens Inhibitor of nuclear factor kappa-B kinase subunit beta Proteins 0.000 description 6
102000008394 Immunoglobulin Fragments Human genes 0.000 description 6
108010021625 Immunoglobulin Fragments Proteins 0.000 description 6
102100021854 Inhibitor of nuclear factor kappa-B kinase subunit beta Human genes 0.000 description 6
108010055717 JNK Mitogen-Activated Protein Kinases Proteins 0.000 description 6
102000019145 JUN kinase activity proteins Human genes 0.000 description 6
108010018242 Transcription Factor AP-1 Proteins 0.000 description 6
238000001042 affinity chromatography Methods 0.000 description 6
210000004899 c-terminal region Anatomy 0.000 description 6
230000008859 change Effects 0.000 description 6
230000034994 death Effects 0.000 description 6
230000001419 dependent effect Effects 0.000 description 6
238000001727 in vivo Methods 0.000 description 6
238000011065 in-situ storage Methods 0.000 description 6
239000000411 inducer Substances 0.000 description 6
230000031146 intracellular signal transduction Effects 0.000 description 6
230000036961 partial effect Effects 0.000 description 6
230000034190 positive regulation of NF-kappaB transcription factor activity Effects 0.000 description 6
235000019419 proteases Nutrition 0.000 description 6
101150028668 APO1 gene Proteins 0.000 description 5
102100025064 Cellular tumor antigen p53 Human genes 0.000 description 5
108020004705 Codon Proteins 0.000 description 5
102100026693 FAS-associated death domain protein Human genes 0.000 description 5
101000721661 Homo sapiens Cellular tumor antigen p53 Proteins 0.000 description 5
101000950695 Homo sapiens Mitogen-activated protein kinase 8 Proteins 0.000 description 5
101000611023 Homo sapiens Tumor necrosis factor receptor superfamily member 6 Proteins 0.000 description 5
102100037808 Mitogen-activated protein kinase 8 Human genes 0.000 description 5
241000283973 Oryctolagus cuniculus Species 0.000 description 5
241000276498 Pollachius virens Species 0.000 description 5
210000001744 T-lymphocyte Anatomy 0.000 description 5
102100031988 Tumor necrosis factor ligand superfamily member 6 Human genes 0.000 description 5
108050002568 Tumor necrosis factor ligand superfamily member 6 Proteins 0.000 description 5
102100040403 Tumor necrosis factor receptor superfamily member 6 Human genes 0.000 description 5
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 5
230000002776 aggregation Effects 0.000 description 5
238000004220 aggregation Methods 0.000 description 5
230000003197 catalytic effect Effects 0.000 description 5
101150055276 ced-3 gene Proteins 0.000 description 5
210000000170 cell membrane Anatomy 0.000 description 5
230000000295 complement effect Effects 0.000 description 5
238000013461 design Methods 0.000 description 5
230000002708 enhancing effect Effects 0.000 description 5
239000000284 extract Substances 0.000 description 5
102000034356 gene-regulatory proteins Human genes 0.000 description 5
108091006104 gene-regulatory proteins Proteins 0.000 description 5
230000002757 inflammatory effect Effects 0.000 description 5
238000002372 labelling Methods 0.000 description 5
230000007246 mechanism Effects 0.000 description 5
150000007523 nucleic acids Chemical class 0.000 description 5
238000003127 radioimmunoassay Methods 0.000 description 5
230000002441 reversible effect Effects 0.000 description 5
210000002966 serum Anatomy 0.000 description 5
241000894007 species Species 0.000 description 5
238000003786 synthesis reaction Methods 0.000 description 5
125000001433 C-terminal amino-acid group Chemical group 0.000 description 4
102000001477 Deubiquitinating Enzymes Human genes 0.000 description 4
108010093668 Deubiquitinating Enzymes Proteins 0.000 description 4
101000979919 Homo sapiens Cell growth regulator with EF hand domain protein 1 Proteins 0.000 description 4
230000005049 JUN phosphorylation Effects 0.000 description 4
ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 4
108010047294 Lamins Proteins 0.000 description 4
102000006835 Lamins Human genes 0.000 description 4
ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 4
102000035181 adaptor proteins Human genes 0.000 description 4
108091005764 adaptor proteins Proteins 0.000 description 4
238000007792 addition Methods 0.000 description 4
239000002671 adjuvant Substances 0.000 description 4
210000003719 b-lymphocyte Anatomy 0.000 description 4
239000000969 carrier Substances 0.000 description 4
238000003776 cleavage reaction Methods 0.000 description 4
230000000445 cytocidal effect Effects 0.000 description 4
239000003623 enhancer Substances 0.000 description 4
230000004927 fusion Effects 0.000 description 4
230000009931 harmful effect Effects 0.000 description 4
238000009396 hybridization Methods 0.000 description 4
230000003053 immunization Effects 0.000 description 4
238000001114 immunoprecipitation Methods 0.000 description 4
230000000977 initiatory effect Effects 0.000 description 4
238000011835 investigation Methods 0.000 description 4
238000000021 kinase assay Methods 0.000 description 4
210000005053 lamin Anatomy 0.000 description 4
102000039446 nucleic acids Human genes 0.000 description 4
108020004707 nucleic acids Proteins 0.000 description 4
108020003519 protein disulfide isomerase Proteins 0.000 description 4
230000007017 scission Effects 0.000 description 4
238000012216 screening Methods 0.000 description 4
230000008093 supporting effect Effects 0.000 description 4
238000001890 transfection Methods 0.000 description 4
238000003160 two-hybrid assay Methods 0.000 description 4
241001515965 unidentified phage Species 0.000 description 4
208000030507 AIDS Diseases 0.000 description 3
102100023995 Beta-nerve growth factor Human genes 0.000 description 3
102100024851 Cell growth regulator with EF hand domain protein 1 Human genes 0.000 description 3
108010077544 Chromatin Proteins 0.000 description 3
102000004127 Cytokines Human genes 0.000 description 3
108090000695 Cytokines Proteins 0.000 description 3
102100020743 Dipeptidase 1 Human genes 0.000 description 3
108010077716 Fas-Associated Death Domain Protein Proteins 0.000 description 3
241000282412 Homo Species 0.000 description 3
108010001336 Horseradish Peroxidase Proteins 0.000 description 3
108060003951 Immunoglobulin Proteins 0.000 description 3
108091008604 NGF receptors Proteins 0.000 description 3
229920001213 Polysorbate 20 Polymers 0.000 description 3
101710187830 Tumor necrosis factor receptor superfamily member 1B Proteins 0.000 description 3
230000003213 activating effect Effects 0.000 description 3
125000002252 acyl group Chemical group 0.000 description 3
239000011324 bead Substances 0.000 description 3
239000012472 biological sample Substances 0.000 description 3
229960002685 biotin Drugs 0.000 description 3
235000020958 biotin Nutrition 0.000 description 3
239000011616 biotin Substances 0.000 description 3
230000000903 blocking effect Effects 0.000 description 3
230000010261 cell growth Effects 0.000 description 3
239000013592 cell lysate Substances 0.000 description 3
239000007795 chemical reaction product Substances 0.000 description 3
210000003483 chromatin Anatomy 0.000 description 3
238000010276 construction Methods 0.000 description 3
210000000805 cytoplasm Anatomy 0.000 description 3
230000001066 destructive effect Effects 0.000 description 3
230000005014 ectopic expression Effects 0.000 description 3
210000002950 fibroblast Anatomy 0.000 description 3
230000012010 growth Effects 0.000 description 3
RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
102000018358 immunoglobulin Human genes 0.000 description 3
238000013198 immunometric assay Methods 0.000 description 3
230000001939 inductive effect Effects 0.000 description 3
239000007924 injection Substances 0.000 description 3
238000002347 injection Methods 0.000 description 3
239000007788 liquid Substances 0.000 description 3
210000004698 lymphocyte Anatomy 0.000 description 3
239000006166 lysate Substances 0.000 description 3
229910052751 metal Inorganic materials 0.000 description 3
239000002184 metal Substances 0.000 description 3
210000004897 n-terminal region Anatomy 0.000 description 3
239000013642 negative control Substances 0.000 description 3
235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 3
239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 3
230000004952 protein activity Effects 0.000 description 3
238000000159 protein binding assay Methods 0.000 description 3
230000004850 protein–protein interaction Effects 0.000 description 3
230000002829 reductive effect Effects 0.000 description 3
125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 3
230000007781 signaling event Effects 0.000 description 3
238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 3
238000001086 yeast two-hybrid system Methods 0.000 description 3
HQFLTUZKIRYQSP-UHFFFAOYSA-N 3-ethyl-2h-1,3-benzothiazole-6-sulfonic acid Chemical compound OS(=O)(=O)C1=CC=C2N(CC)CSC2=C1 HQFLTUZKIRYQSP-UHFFFAOYSA-N 0.000 description 2
QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
206010003445 Ascites Diseases 0.000 description 2
238000011725 BALB/c mouse Methods 0.000 description 2
241000894006 Bacteria Species 0.000 description 2
241000283707 Capra Species 0.000 description 2
102000053602 DNA Human genes 0.000 description 2
230000004544 DNA amplification Effects 0.000 description 2
230000006820 DNA synthesis Effects 0.000 description 2
101000823179 Danio rerio RUN domain-containing protein 3A Proteins 0.000 description 2
238000002965 ELISA Methods 0.000 description 2
241000588724 Escherichia coli Species 0.000 description 2
HVLSXIKZNLPZJJ-TXZCQADKSA-N HA peptide Chemical group C([C@@H](C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](C)C(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 HVLSXIKZNLPZJJ-TXZCQADKSA-N 0.000 description 2
101000911074 Homo sapiens FAS-associated death domain protein Proteins 0.000 description 2
101000992283 Homo sapiens Optineurin Proteins 0.000 description 2
101001130441 Homo sapiens Ras-related protein Rap-2a Proteins 0.000 description 2
101000850748 Homo sapiens Tumor necrosis factor receptor type 1-associated DEATH domain protein Proteins 0.000 description 2
OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
101710154541 Modulator protein Proteins 0.000 description 2
125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 2
208000009869 Neu-Laxova syndrome Diseases 0.000 description 2
238000000636 Northern blotting Methods 0.000 description 2
108010077850 Nuclear Localization Signals Proteins 0.000 description 2
102000012338 Poly(ADP-ribose) Polymerases Human genes 0.000 description 2
108010061844 Poly(ADP-ribose) Polymerases Proteins 0.000 description 2
229920000776 Poly(Adenosine diphosphate-ribose) polymerase Polymers 0.000 description 2
239000004793 Polystyrene Substances 0.000 description 2
108010068086 Polyubiquitin Proteins 0.000 description 2
102100037935 Polyubiquitin-C Human genes 0.000 description 2
108010076504 Protein Sorting Signals Proteins 0.000 description 2
102100031420 Ras-related protein Rap-2a Human genes 0.000 description 2
108020004511 Recombinant DNA Proteins 0.000 description 2
108700008625 Reporter Genes Proteins 0.000 description 2
101100421708 Schistosoma mansoni SM20 gene Proteins 0.000 description 2
238000012300 Sequence Analysis Methods 0.000 description 2
238000002105 Southern blotting Methods 0.000 description 2
108091081024 Start codon Proteins 0.000 description 2
101150009046 Tnfrsf1a gene Proteins 0.000 description 2
102100033081 Tumor necrosis factor receptor type 1-associated DEATH domain protein Human genes 0.000 description 2
108090000848 Ubiquitin Proteins 0.000 description 2
102000044159 Ubiquitin Human genes 0.000 description 2
102000006275 Ubiquitin-Protein Ligases Human genes 0.000 description 2
108010083111 Ubiquitin-Protein Ligases Proteins 0.000 description 2
231100000354 acute hepatitis Toxicity 0.000 description 2
239000005557 antagonist Substances 0.000 description 2
OHDRQQURAXLVGJ-HLVWOLMTSA-N azane;(2e)-3-ethyl-2-[(e)-(3-ethyl-6-sulfo-1,3-benzothiazol-2-ylidene)hydrazinylidene]-1,3-benzothiazole-6-sulfonic acid Chemical compound [NH4+].[NH4+].S/1C2=CC(S([O-])(=O)=O)=CC=C2N(CC)C\1=N/N=C1/SC2=CC(S([O-])(=O)=O)=CC=C2N1CC OHDRQQURAXLVGJ-HLVWOLMTSA-N 0.000 description 2
230000008827 biological function Effects 0.000 description 2
230000033228 biological regulation Effects 0.000 description 2
108010053098 biotin receptor Proteins 0.000 description 2
210000004556 brain Anatomy 0.000 description 2
239000000872 buffer Substances 0.000 description 2
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
238000004113 cell culture Methods 0.000 description 2
125000003636 chemical group Chemical group 0.000 description 2
108091006116 chimeric peptides Proteins 0.000 description 2
230000021615 conjugation Effects 0.000 description 2
230000001086 cytosolic effect Effects 0.000 description 2
230000006378 damage Effects 0.000 description 2
238000006471 dimerization reaction Methods 0.000 description 2
230000003828 downregulation Effects 0.000 description 2
230000009977 dual effect Effects 0.000 description 2
230000004064 dysfunction Effects 0.000 description 2
239000012636 effector Substances 0.000 description 2
239000007850 fluorescent dye Substances 0.000 description 2
229940014144 folate Drugs 0.000 description 2
102000006815 folate receptor Human genes 0.000 description 2
108020005243 folate receptor Proteins 0.000 description 2
OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
235000019152 folic acid Nutrition 0.000 description 2
239000011724 folic acid Substances 0.000 description 2
125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
230000028993 immune response Effects 0.000 description 2
238000002649 immunization Methods 0.000 description 2
238000003018 immunoassay Methods 0.000 description 2
230000005847 immunogenicity Effects 0.000 description 2
230000028709 inflammatory response Effects 0.000 description 2
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
230000004807 localization Effects 0.000 description 2
238000004020 luminiscence type Methods 0.000 description 2
125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 2
238000005259 measurement Methods 0.000 description 2
150000002739 metals Chemical class 0.000 description 2
238000002156 mixing Methods 0.000 description 2
238000002515 oligonucleotide synthesis Methods 0.000 description 2
238000010647 peptide synthesis reaction Methods 0.000 description 2
239000013600 plasmid vector Substances 0.000 description 2
229920000642 polymer Polymers 0.000 description 2
229920002223 polystyrene Polymers 0.000 description 2
230000023603 positive regulation of transcription initiation, DNA-dependent Effects 0.000 description 2
XOJVVFBFDXDTEG-UHFFFAOYSA-N pristane Chemical compound CC(C)CCCC(C)CCCC(C)CCCC(C)C XOJVVFBFDXDTEG-UHFFFAOYSA-N 0.000 description 2
230000000770 proinflammatory effect Effects 0.000 description 2
230000001737 promoting effect Effects 0.000 description 2
230000017854 proteolysis Effects 0.000 description 2
238000000746 purification Methods 0.000 description 2
238000000163 radioactive labelling Methods 0.000 description 2
230000007115 recruitment Effects 0.000 description 2
230000003938 response to stress Effects 0.000 description 2
238000012163 sequencing technique Methods 0.000 description 2
230000008054 signal transmission Effects 0.000 description 2
239000000126 substance Substances 0.000 description 2
239000006228 supernatant Substances 0.000 description 2
201000000596 systemic lupus erythematosus Diseases 0.000 description 2
230000001225 therapeutic effect Effects 0.000 description 2
230000000451 tissue damage Effects 0.000 description 2
231100000827 tissue damage Toxicity 0.000 description 2
238000013519 translation Methods 0.000 description 2
230000032895 transmembrane transport Effects 0.000 description 2
230000032258 transport Effects 0.000 description 2
230000001960 triggered effect Effects 0.000 description 2
238000010798 ubiquitination Methods 0.000 description 2
230000034512 ubiquitination Effects 0.000 description 2
230000035899 viability Effects 0.000 description 2
230000000007 visual effect Effects 0.000 description 2
ALZSTTDFHZHSCA-RNVDEAKXSA-N (4s)-4-[[(2s)-2-acetamido-3-carboxypropanoyl]amino]-5-[[(2s)-1-[[(2s)-3-carboxy-1-[(4-methyl-2-oxochromen-7-yl)amino]-1-oxopropan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-5-oxopentanoic acid Chemical compound CC1=CC(=O)OC2=CC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(O)=O)NC(C)=O)C(C)C)=CC=C21 ALZSTTDFHZHSCA-RNVDEAKXSA-N 0.000 description 1
102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
TWJNQYPJQDRXPH-UHFFFAOYSA-N 2-cyanobenzohydrazide Chemical compound NNC(=O)C1=CC=CC=C1C#N TWJNQYPJQDRXPH-UHFFFAOYSA-N 0.000 description 1
HUDPLKWXRLNSPC-UHFFFAOYSA-N 4-aminophthalhydrazide Chemical compound O=C1NNC(=O)C=2C1=CC(N)=CC=2 HUDPLKWXRLNSPC-UHFFFAOYSA-N 0.000 description 1
102100031126 6-phosphogluconolactonase Human genes 0.000 description 1
108010029731 6-phosphogluconolactonase Proteins 0.000 description 1
108010021160 Ac-aspartyl-glutamyl-valyl-aspartyl-aminomethylcoumarin Proteins 0.000 description 1
108010022752 Acetylcholinesterase Proteins 0.000 description 1
102000012440 Acetylcholinesterase Human genes 0.000 description 1
108010000239 Aequorin Proteins 0.000 description 1
229920000936 Agarose Polymers 0.000 description 1
102000007698 Alcohol dehydrogenase Human genes 0.000 description 1
108010021809 Alcohol dehydrogenase Proteins 0.000 description 1
102000002260 Alkaline Phosphatase Human genes 0.000 description 1
108020004774 Alkaline Phosphatase Proteins 0.000 description 1
108700028369 Alleles Proteins 0.000 description 1
102100040121 Allograft inflammatory factor 1 Human genes 0.000 description 1
102000013142 Amylases Human genes 0.000 description 1
108010065511 Amylases Proteins 0.000 description 1
108010049777 Ankyrins Proteins 0.000 description 1
102000008102 Ankyrins Human genes 0.000 description 1
108020005544 Antisense RNA Proteins 0.000 description 1
108010002913 Asialoglycoproteins Proteins 0.000 description 1
108010024976 Asparaginase Proteins 0.000 description 1
102000015790 Asparaginase Human genes 0.000 description 1
102100026189 Beta-galactosidase Human genes 0.000 description 1
210000001239 CD8-positive, alpha-beta cytotoxic T lymphocyte Anatomy 0.000 description 1
206010006895 Cachexia Diseases 0.000 description 1
101710132601 Capsid protein Proteins 0.000 description 1
108090000426 Caspase-1 Proteins 0.000 description 1
102100029855 Caspase-3 Human genes 0.000 description 1
102100035882 Catalase Human genes 0.000 description 1
108010053835 Catalase Proteins 0.000 description 1
206010057248 Cell death Diseases 0.000 description 1
206010010144 Completed suicide Diseases 0.000 description 1
102100032202 Cornulin Human genes 0.000 description 1
108050006400 Cyclin Proteins 0.000 description 1
102000016736 Cyclin Human genes 0.000 description 1
102000003910 Cyclin D Human genes 0.000 description 1
108090000259 Cyclin D Proteins 0.000 description 1
IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 1
NBSCHQHZLSJFNQ-QTVWNMPRSA-N D-Mannose-6-phosphate Chemical compound OC1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H](O)[C@@H]1O NBSCHQHZLSJFNQ-QTVWNMPRSA-N 0.000 description 1
WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
102000004594 DNA Polymerase I Human genes 0.000 description 1
108010017826 DNA Polymerase I Proteins 0.000 description 1
102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
102100039694 Death-associated protein 1 Human genes 0.000 description 1
206010011953 Decreased activity Diseases 0.000 description 1
CYCGRDQQIOGCKX-UHFFFAOYSA-N Dehydro-luciferin Natural products OC(=O)C1=CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 CYCGRDQQIOGCKX-UHFFFAOYSA-N 0.000 description 1
229920002307 Dextran Polymers 0.000 description 1
239000006144 Dulbecco’s modiﬁed Eagle's medium Substances 0.000 description 1
238000012286 ELISA Assay Methods 0.000 description 1
238000008157 ELISA kit Methods 0.000 description 1
241000702224 Enterobacteria phage M13 Species 0.000 description 1
239000004593 Epoxy Substances 0.000 description 1
BJGNCJDXODQBOB-UHFFFAOYSA-N Fivefly Luciferin Natural products OC(=O)C1CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 BJGNCJDXODQBOB-UHFFFAOYSA-N 0.000 description 1
108010073178 Glucan 1,4-alpha-Glucosidase Proteins 0.000 description 1
102100022624 Glucoamylase Human genes 0.000 description 1
108010018962 Glucosephosphate Dehydrogenase Proteins 0.000 description 1
102000000587 Glycerolphosphate Dehydrogenase Human genes 0.000 description 1
108010041921 Glycerolphosphate Dehydrogenase Proteins 0.000 description 1
108091027305 Heteroduplex Proteins 0.000 description 1
101710186616 Histone acetyltransferase Tip60 Proteins 0.000 description 1
102000006947 Histones Human genes 0.000 description 1
108010033040 Histones Proteins 0.000 description 1
101000793880 Homo sapiens Caspase-3 Proteins 0.000 description 1
101000920981 Homo sapiens Cornulin Proteins 0.000 description 1
101000886250 Homo sapiens Death-associated protein 1 Proteins 0.000 description 1
101001063991 Homo sapiens Leptin Proteins 0.000 description 1
101000686153 Homo sapiens Ras-related GTP-binding protein A Proteins 0.000 description 1
101000665894 Homo sapiens Replication initiator 1 Proteins 0.000 description 1
241000714260 Human T-lymphotropic virus 1 Species 0.000 description 1
241000598171 Human adenovirus sp. Species 0.000 description 1
208000023105 Huntington disease Diseases 0.000 description 1
102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
102000018071 Immunoglobulin Fc Fragments Human genes 0.000 description 1
108010091135 Immunoglobulin Fc Fragments Proteins 0.000 description 1
102000004877 Insulin Human genes 0.000 description 1
108090001061 Insulin Proteins 0.000 description 1
102100034343 Integrase Human genes 0.000 description 1
102000014150 Interferons Human genes 0.000 description 1
108010050904 Interferons Proteins 0.000 description 1
108010002352 Interleukin-1 Proteins 0.000 description 1
102100026879 Interleukin-2 receptor subunit beta Human genes 0.000 description 1
102000001702 Intracellular Signaling Peptides and Proteins Human genes 0.000 description 1
108010068964 Intracellular Signaling Peptides and Proteins Proteins 0.000 description 1
102000004195 Isomerases Human genes 0.000 description 1
108090000769 Isomerases Proteins 0.000 description 1
125000002061 L-isoleucyl group Chemical group [H]N([H])[C@]([H])(C(=O)[*])[C@](C([H])([H])[H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
239000000232 Lipid Bilayer Substances 0.000 description 1
206010067125 Liver injury Diseases 0.000 description 1
DDWFXDSYGUXRAY-UHFFFAOYSA-N Luciferin Natural products CCc1c(C)c(CC2NC(=O)C(=C2C=C)C)[nH]c1Cc3[nH]c4C(=C5/NC(CC(=O)O)C(C)C5CC(=O)O)CC(=O)c4c3C DDWFXDSYGUXRAY-UHFFFAOYSA-N 0.000 description 1
108010047357 Luminescent Proteins Proteins 0.000 description 1
102000006830 Luminescent Proteins Human genes 0.000 description 1
208000030289 Lymphoproliferative disease Diseases 0.000 description 1
102000004083 Lymphotoxin-alpha Human genes 0.000 description 1
108090000542 Lymphotoxin-alpha Proteins 0.000 description 1
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
239000004472 Lysine Substances 0.000 description 1
108091054455 MAP kinase family Proteins 0.000 description 1
102000043136 MAP kinase family Human genes 0.000 description 1
102000018721 Macroglobulins Human genes 0.000 description 1
108010091934 Macroglobulins Proteins 0.000 description 1
102000013460 Malate Dehydrogenase Human genes 0.000 description 1
108010026217 Malate Dehydrogenase Proteins 0.000 description 1
108010059724 Micrococcal Nuclease Proteins 0.000 description 1
241001529936 Murinae Species 0.000 description 1
235000021360 Myristic acid Nutrition 0.000 description 1
TUNFSRHWOTWDNC-UHFFFAOYSA-N Myristic acid Natural products CCCCCCCCCCCCCC(O)=O TUNFSRHWOTWDNC-UHFFFAOYSA-N 0.000 description 1
QPCDCPDFJACHGM-UHFFFAOYSA-N N,N-bis{2-[bis(carboxymethyl)amino]ethyl}glycine Chemical group OC(=O)CN(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CC(O)=O QPCDCPDFJACHGM-UHFFFAOYSA-N 0.000 description 1
108010014632 NF-kappa B kinase Proteins 0.000 description 1
239000000020 Nitrocellulose Substances 0.000 description 1
108091092724 Noncoding DNA Proteins 0.000 description 1
102000007999 Nuclear Proteins Human genes 0.000 description 1
108010089610 Nuclear Proteins Proteins 0.000 description 1
108010047956 Nucleosomes Proteins 0.000 description 1
239000004677 Nylon Substances 0.000 description 1
102000016979 Other receptors Human genes 0.000 description 1
102000004316 Oxidoreductases Human genes 0.000 description 1
108090000854 Oxidoreductases Proteins 0.000 description 1
108090000526 Papain Proteins 0.000 description 1
102000057297 Pepsin A Human genes 0.000 description 1
108090000284 Pepsin A Proteins 0.000 description 1
241000644027 Perideridia lemmonii Species 0.000 description 1
108010004729 Phycoerythrin Proteins 0.000 description 1
206010035226 Plasma cell myeloma Diseases 0.000 description 1
239000004698 Polyethylene Substances 0.000 description 1
239000004743 Polypropylene Substances 0.000 description 1
108010002519 Prolactin Receptors Proteins 0.000 description 1
102100029000 Prolactin receptor Human genes 0.000 description 1
101710132570 Protein G1 Proteins 0.000 description 1
102000001253 Protein Kinase Human genes 0.000 description 1
102000012515 Protein kinase domains Human genes 0.000 description 1
108050002122 Protein kinase domains Proteins 0.000 description 1
102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
102000009572 RNA Polymerase II Human genes 0.000 description 1
108010009460 RNA Polymerase II Proteins 0.000 description 1
239000013614 RNA sample Substances 0.000 description 1
108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
238000010240 RT-PCR analysis Methods 0.000 description 1
102100025001 Ras-related GTP-binding protein A Human genes 0.000 description 1
108091081062 Repeated sequence (DNA) Proteins 0.000 description 1
102100038242 Replication initiator 1 Human genes 0.000 description 1
208000025747 Rheumatic disease Diseases 0.000 description 1
102000006382 Ribonucleases Human genes 0.000 description 1
108010083644 Ribonucleases Proteins 0.000 description 1
MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
102000036646 Signalosomes Human genes 0.000 description 1
108091007411 Signalosomes Proteins 0.000 description 1
108020004682 Single-Stranded DNA Proteins 0.000 description 1
102220474382 Solute carrier family 13 member 3_S48A_mutation Human genes 0.000 description 1
101710120037 Toxin CcdB Proteins 0.000 description 1
102000011409 Transcobalamins Human genes 0.000 description 1
108010023603 Transcobalamins Proteins 0.000 description 1
102000004338 Transferrin Human genes 0.000 description 1
108090000901 Transferrin Proteins 0.000 description 1
206010052779 Transplant rejections Diseases 0.000 description 1
102000005924 Triose-Phosphate Isomerase Human genes 0.000 description 1
108700015934 Triose-phosphate isomerases Proteins 0.000 description 1
101710187743 Tumor necrosis factor receptor superfamily member 1A Proteins 0.000 description 1
108010046334 Urease Proteins 0.000 description 1
206010046865 Vaccinia virus infection Diseases 0.000 description 1
108010067390 Viral Proteins Proteins 0.000 description 1
208000036142 Viral infection Diseases 0.000 description 1
229930003779 Vitamin B12 Natural products 0.000 description 1
HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
230000007488 abnormal function Effects 0.000 description 1
230000035508 accumulation Effects 0.000 description 1
238000009825 accumulation Methods 0.000 description 1
125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
229940022698 acetylcholinesterase Drugs 0.000 description 1
DZBUGLKDJFMEHC-UHFFFAOYSA-N acridine Chemical class C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 description 1
239000012190 activator Substances 0.000 description 1
239000004480 active ingredient Substances 0.000 description 1
231100000439 acute liver injury Toxicity 0.000 description 1
210000001789 adipocyte Anatomy 0.000 description 1
125000001931 aliphatic group Chemical group 0.000 description 1
WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
230000004075 alteration Effects 0.000 description 1
150000001408 amides Chemical class 0.000 description 1
125000003277 amino group Chemical group 0.000 description 1
229910021529 ammonia Inorganic materials 0.000 description 1
235000019418 amylase Nutrition 0.000 description 1
229940025131 amylases Drugs 0.000 description 1
208000022531 anorexia Diseases 0.000 description 1
230000000844 anti-bacterial effect Effects 0.000 description 1
230000036436 anti-hiv Effects 0.000 description 1
230000003110 anti-inflammatory effect Effects 0.000 description 1
230000000259 anti-tumor effect Effects 0.000 description 1
230000002155 anti-virotic effect Effects 0.000 description 1
230000000890 antigenic effect Effects 0.000 description 1
229960005475 antiinfective agent Drugs 0.000 description 1
239000004599 antimicrobial Substances 0.000 description 1
239000002246 antineoplastic agent Substances 0.000 description 1
125000003435 aroyl group Chemical group 0.000 description 1
229960003272 asparaginase Drugs 0.000 description 1
235000003704 aspartic acid Nutrition 0.000 description 1
CKLJMWTZIZZHCS-REOHCLBHSA-N aspartic acid group Chemical group N[C@@H](CC(=O)O)C(=O)O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
230000001363 autoimmune Effects 0.000 description 1
238000000376 autoradiography Methods 0.000 description 1
239000013602 bacteriophage vector Substances 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
108010005774 beta-Galactosidase Proteins 0.000 description 1
OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
239000013060 biological fluid Substances 0.000 description 1
238000005415 bioluminescence Methods 0.000 description 1
230000029918 bioluminescence Effects 0.000 description 1
230000002051 biphasic effect Effects 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000008280 blood Substances 0.000 description 1
201000011510 cancer Diseases 0.000 description 1
150000001720 carbohydrates Chemical group 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
230000022131 cell cycle Effects 0.000 description 1
238000010822 cell death assay Methods 0.000 description 1
230000015861 cell surface binding Effects 0.000 description 1
230000007248 cellular mechanism Effects 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
235000010980 cellulose Nutrition 0.000 description 1
239000003593 chromogenic compound Substances 0.000 description 1
230000004186 co-expression Effects 0.000 description 1
AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 1
238000004737 colorimetric analysis Methods 0.000 description 1
239000003184 complementary RNA Substances 0.000 description 1
230000009918 complex formation Effects 0.000 description 1
108091036078 conserved sequence Proteins 0.000 description 1
230000001276 controlling effect Effects 0.000 description 1
230000008878 coupling Effects 0.000 description 1
238000010168 coupling process Methods 0.000 description 1
238000005859 coupling reaction Methods 0.000 description 1
238000004132 cross linking Methods 0.000 description 1
239000012228 culture supernatant Substances 0.000 description 1
230000009089 cytolysis Effects 0.000 description 1
210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
239000003145 cytotoxic factor Substances 0.000 description 1
206010061428 decreased appetite Diseases 0.000 description 1
230000007123 defense Effects 0.000 description 1
230000002950 deficient Effects 0.000 description 1
238000006731 degradation reaction Methods 0.000 description 1
238000011161 development Methods 0.000 description 1
206010012601 diabetes mellitus Diseases 0.000 description 1
238000003745 diagnosis Methods 0.000 description 1
238000010586 diagram Methods 0.000 description 1
238000010790 dilution Methods 0.000 description 1
239000012895 dilution Substances 0.000 description 1
238000003113 dilution method Methods 0.000 description 1
208000035475 disorder Diseases 0.000 description 1
238000006073 displacement reaction Methods 0.000 description 1
238000009826 distribution Methods 0.000 description 1
239000000975 dye Substances 0.000 description 1
230000002900 effect on cell Effects 0.000 description 1
230000000464 effect on transcription Effects 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
230000001159 endocytotic effect Effects 0.000 description 1
238000006911 enzymatic reaction Methods 0.000 description 1
238000000605 extraction Methods 0.000 description 1
230000001605 fetal effect Effects 0.000 description 1
238000001914 filtration Methods 0.000 description 1
239000012530 fluid Substances 0.000 description 1
ZFKJVJIDPQDDFY-UHFFFAOYSA-N fluorescamine Chemical compound C12=CC=CC=C2C(=O)OC1(C1=O)OC=C1C1=CC=CC=C1 ZFKJVJIDPQDDFY-UHFFFAOYSA-N 0.000 description 1
MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
238000005194 fractionation Methods 0.000 description 1
230000005714 functional activity Effects 0.000 description 1
125000000524 functional group Chemical group 0.000 description 1
108020001507 fusion proteins Proteins 0.000 description 1
102000037865 fusion proteins Human genes 0.000 description 1
230000000799 fusogenic effect Effects 0.000 description 1
229930182830 galactose Natural products 0.000 description 1
238000003167 genetic complementation Methods 0.000 description 1
239000011521 glass Substances 0.000 description 1
125000003712 glycosamine group Chemical group 0.000 description 1
210000003714 granulocyte Anatomy 0.000 description 1
239000003102 growth factor Substances 0.000 description 1
230000035876 healing Effects 0.000 description 1
210000002216 heart Anatomy 0.000 description 1
IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 1
102000049953 human LEP Human genes 0.000 description 1
229910052739 hydrogen Inorganic materials 0.000 description 1
239000001257 hydrogen Substances 0.000 description 1
238000010166 immunofluorescence Methods 0.000 description 1
238000010820 immunofluorescence microscopy Methods 0.000 description 1
230000002163 immunogen Effects 0.000 description 1
229940072221 immunoglobulins Drugs 0.000 description 1
230000001771 impaired effect Effects 0.000 description 1
238000000126 in silico method Methods 0.000 description 1
238000010348 incorporation Methods 0.000 description 1
239000012678 infectious agent Substances 0.000 description 1
229940125396 insulin Drugs 0.000 description 1
230000002452 interceptive effect Effects 0.000 description 1
229940079322 interferon Drugs 0.000 description 1
230000006662 intracellular pathway Effects 0.000 description 1
150000002500 ions Chemical class 0.000 description 1
SZVJSHCCFOBDDC-UHFFFAOYSA-N iron(II,III) oxide Inorganic materials O=[Fe]O[Fe]O[Fe]=O SZVJSHCCFOBDDC-UHFFFAOYSA-N 0.000 description 1
210000003734 kidney Anatomy 0.000 description 1
238000011005 laboratory method Methods 0.000 description 1
229910052747 lanthanoid Inorganic materials 0.000 description 1
150000002602 lanthanoids Chemical class 0.000 description 1
208000032839 leukemia Diseases 0.000 description 1
210000000265 leukocyte Anatomy 0.000 description 1
108020001756 ligand binding domains Proteins 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
210000005229 liver cell Anatomy 0.000 description 1
230000033001 locomotion Effects 0.000 description 1
150000004668 long chain fatty acids Chemical class 0.000 description 1
238000003670 luciferase enzyme activity assay Methods 0.000 description 1
HWYHZTIRURJOHG-UHFFFAOYSA-N luminol Chemical compound O=C1NNC(=O)C2=C1C(N)=CC=C2 HWYHZTIRURJOHG-UHFFFAOYSA-N 0.000 description 1
210000001165 lymph node Anatomy 0.000 description 1
201000001268 lymphoproliferative syndrome Diseases 0.000 description 1
229920002521 macromolecule Polymers 0.000 description 1
230000014759 maintenance of location Effects 0.000 description 1
210000001161 mammalian embryo Anatomy 0.000 description 1
238000013507 mapping Methods 0.000 description 1
239000003550 marker Substances 0.000 description 1
239000000463 material Substances 0.000 description 1
230000035800 maturation Effects 0.000 description 1
238000001466 metabolic labeling Methods 0.000 description 1
TWXDDNPPQUTEOV-FVGYRXGTSA-N methamphetamine hydrochloride Chemical compound Cl.CN[C@@H](C)CC1=CC=CC=C1 TWXDDNPPQUTEOV-FVGYRXGTSA-N 0.000 description 1
238000000386 microscopy Methods 0.000 description 1
230000003228 microsomal effect Effects 0.000 description 1
238000010369 molecular cloning Methods 0.000 description 1
210000002864 mononuclear phagocyte Anatomy 0.000 description 1
201000006417 multiple sclerosis Diseases 0.000 description 1
238000002703 mutagenesis Methods 0.000 description 1
231100000350 mutagenesis Toxicity 0.000 description 1
201000000050 myeloid neoplasm Diseases 0.000 description 1
UPSFMJHZUCSEHU-JYGUBCOQSA-N n-[(2s,3r,4r,5s,6r)-2-[(2r,3s,4r,5r,6s)-5-acetamido-4-hydroxy-2-(hydroxymethyl)-6-(4-methyl-2-oxochromen-7-yl)oxyoxan-3-yl]oxy-4,5-dihydroxy-6-(hydroxymethyl)oxan-3-yl]acetamide Chemical compound CC(=O)N[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@H]1[C@H](O)[C@@H](NC(C)=O)[C@H](OC=2C=C3OC(=O)C=C(C)C3=CC=2)O[C@@H]1CO UPSFMJHZUCSEHU-JYGUBCOQSA-N 0.000 description 1
229920001220 nitrocellulos Polymers 0.000 description 1
230000002020 noncytotoxic effect Effects 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
210000001623 nucleosome Anatomy 0.000 description 1
210000004940 nucleus Anatomy 0.000 description 1
230000030648 nucleus localization Effects 0.000 description 1
235000015097 nutrients Nutrition 0.000 description 1
229920001778 nylon Polymers 0.000 description 1
230000003287 optical effect Effects 0.000 description 1
150000002894 organic compounds Chemical class 0.000 description 1
238000012261 overproduction Methods 0.000 description 1
210000000496 pancreas Anatomy 0.000 description 1
229940055729 papain Drugs 0.000 description 1
235000019834 papain Nutrition 0.000 description 1
239000002245 particle Substances 0.000 description 1
230000001717 pathogenic effect Effects 0.000 description 1
230000001575 pathological effect Effects 0.000 description 1
230000007119 pathological manifestation Effects 0.000 description 1
229960003330 pentetic acid Drugs 0.000 description 1
229940111202 pepsin Drugs 0.000 description 1
230000007030 peptide scission Effects 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
239000002831 pharmacologic agent Substances 0.000 description 1
RXNXLAHQOVLMIE-UHFFFAOYSA-N phenyl 10-methylacridin-10-ium-9-carboxylate Chemical compound C12=CC=CC=C2[N+](C)=C2C=CC=CC2=C1C(=O)OC1=CC=CC=C1 RXNXLAHQOVLMIE-UHFFFAOYSA-N 0.000 description 1
125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
238000003566 phosphorylation assay Methods 0.000 description 1
ZWLUXSQADUDCSB-UHFFFAOYSA-N phthalaldehyde Chemical compound O=CC1=CC=CC=C1C=O ZWLUXSQADUDCSB-UHFFFAOYSA-N 0.000 description 1
229920002401 polyacrylamide Polymers 0.000 description 1
238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
229920000573 polyethylene Polymers 0.000 description 1
230000000379 polymerizing effect Effects 0.000 description 1
229920001155 polypropylene Polymers 0.000 description 1
230000008092 positive effect Effects 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
150000003141 primary amines Chemical class 0.000 description 1
238000012545 processing Methods 0.000 description 1
239000000047 product Substances 0.000 description 1
230000035755 proliferation Effects 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
235000019833 protease Nutrition 0.000 description 1
230000001681 protective effect Effects 0.000 description 1
230000012846 protein folding Effects 0.000 description 1
230000004853 protein function Effects 0.000 description 1
108060006633 protein kinase Proteins 0.000 description 1
230000006337 proteolytic cleavage Effects 0.000 description 1
230000002285 radioactive effect Effects 0.000 description 1
238000010188 recombinant method Methods 0.000 description 1
230000009711 regulatory function Effects 0.000 description 1
230000002040 relaxant effect Effects 0.000 description 1
230000010076 replication Effects 0.000 description 1
238000011160 research Methods 0.000 description 1
238000012552 review Methods 0.000 description 1
PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
150000003335 secondary amines Chemical class 0.000 description 1
238000013207 serial dilution Methods 0.000 description 1
230000009870 specific binding Effects 0.000 description 1
210000000952 spleen Anatomy 0.000 description 1
210000004989 spleen cell Anatomy 0.000 description 1
238000007447 staining method Methods 0.000 description 1
238000012289 standard assay Methods 0.000 description 1
239000007858 starting material Substances 0.000 description 1
230000004936 stimulating effect Effects 0.000 description 1
238000003756 stirring Methods 0.000 description 1
238000005728 strengthening Methods 0.000 description 1
230000001629 suppression Effects 0.000 description 1
239000000725 suspension Substances 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
230000008685 targeting Effects 0.000 description 1
238000012360 testing method Methods 0.000 description 1
125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 1
238000004448 titration Methods 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
238000010361 transduction Methods 0.000 description 1
230000026683 transduction Effects 0.000 description 1
238000012546 transfer Methods 0.000 description 1
239000012581 transferrin Substances 0.000 description 1
230000009466 transformation Effects 0.000 description 1
230000005945 translocation Effects 0.000 description 1
241001430294 unidentified retrovirus Species 0.000 description 1
238000011144 upstream manufacturing Methods 0.000 description 1
VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
208000007089 vaccinia Diseases 0.000 description 1
210000005166 vasculature Anatomy 0.000 description 1
239000003981 vehicle Substances 0.000 description 1
230000009385 viral infection Effects 0.000 description 1
239000013603 viral vector Substances 0.000 description 1
239000011715 vitamin B12 Substances 0.000 description 1
235000019163 vitamin B12 Nutrition 0.000 description 1
238000005406 washing Methods 0.000 description 1
208000016261 weight loss Diseases 0.000 description 1
230000004580 weight loss Effects 0.000 description 1
210000005253 yeast cell Anatomy 0.000 description 1
229910052725 zinc Inorganic materials 0.000 description 1
239000011701 zinc Substances 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
- C07K14/4703—Inhibitors; Suppressors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Zoology (AREA)
Biochemistry (AREA)
Biomedical Technology (AREA)
Biophysics (AREA)
Toxicology (AREA)
Wood Science & Technology (AREA)
Gastroenterology & Hepatology (AREA)
Biotechnology (AREA)
General Engineering & Computer Science (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Bioinformatics & Cheminformatics (AREA)
Virology (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Physics & Mathematics (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Plant Pathology (AREA)
Tropical Medicine & Parasitology (AREA)
Microbiology (AREA)
AIDS & HIV (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

NO20004649A 1998-03-19 2000-09-18 DNA-sekvens, replikerbar ekspresjonsvektor, transformert eukaryot eller prokaryot vertscelle; RAP-2 protein, isoform, fragment, funksjonell analog eller derivater derav samt fremgangsmate for fremstilling og anvendelse derav; farmasoytisk preparat, anvendelse av en rekombinant dyrevirusvektor og en vektor kodende for ribozym sekvens. NO327854B1 (no)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
IL12375898A IL123758A0 (en)	1998-03-19	1998-03-19	Modulators of the function of receptors of the TNF/NGF receptor family and other proteins
IL12602498A IL126024A0 (en)	1998-03-19	1998-09-01	Modulators of the function of receptors of the tnf/ngf receptor family and other proteins
PCT/IL1999/000158 WO1999047672A1 (fr)	1998-03-19	1999-03-18	Modulateurs de la fonction de recepteurs de la famille des recepteurs tnf/ngf et d'autres proteines
CA002323637A CA2323637A1 (fr)	1998-03-19	1999-03-18	Modulateurs de la fonction de recepteurs de la famille des recepteurs tnf/ngf et d'autres proteines

Publications (3)

Publication Number	Publication Date
NO20004649D0 NO20004649D0 (no)	2000-09-18
NO20004649L NO20004649L (no)	2000-10-30
NO327854B1 true NO327854B1 (no)	2009-10-05

Family

ID=39598416

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20004649A NO327854B1 (no)	1998-03-19	2000-09-18	DNA-sekvens, replikerbar ekspresjonsvektor, transformert eukaryot eller prokaryot vertscelle; RAP-2 protein, isoform, fragment, funksjonell analog eller derivater derav samt fremgangsmate for fremstilling og anvendelse derav; farmasoytisk preparat, anvendelse av en rekombinant dyrevirusvektor og en vektor kodende for ribozym sekvens.

Country Status (23)

Country	Link
US (1)	US6734174B1 (fr)
EP (1)	EP1062336B1 (fr)
JP (1)	JP4351389B2 (fr)
KR (1)	KR100748293B1 (fr)
CN (1)	CN1232641C (fr)
AT (1)	ATE318310T1 (fr)
AU (1)	AU760900B2 (fr)
BG (2)	BG64990B1 (fr)
BR (1)	BR9909659A (fr)
CA (2)	CA2323637A1 (fr)
DE (1)	DE69929958T2 (fr)
DK (1)	DK1062336T3 (fr)
EA (1)	EA004062B1 (fr)
EE (1)	EE200000538A (fr)
ES (1)	ES2258838T3 (fr)
HU (1)	HUP0101612A3 (fr)
IL (1)	IL126024A0 (fr)
NO (1)	NO327854B1 (fr)
NZ (2)	NZ525566A (fr)
PL (1)	PL200763B1 (fr)
PT (1)	PT1062336E (fr)
SK (1)	SK285804B6 (fr)
WO (1)	WO1999047672A1 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7189832B1 (en) *	1998-08-20	2007-03-13	The Regents Of The University Of California	Gamma subunit of cytokine responsive IκB-alpha kinase complex and methods of using same
US7745579B1 (en)	1998-09-01	2010-06-29	David Wallach	Inhibitor of NF-KB activation
CA2451955C (fr)	2001-06-26	2015-09-29	Abgenix, Inc.	Anticorps opgl
US7521534B1 (en) *	2003-03-03	2009-04-21	The University Board Of Regents Of Texas System	IKK gamma gene products and methods for making and using same
BRPI0414714A (pt) *	2003-09-24	2006-11-21	Pasteur Institut	polinucleotìdeo purificado, vetor, célula hospedeira, construto de fusão de polipeptìdeo, métodos de inibir a rota de sinalização de nf-capab, de interromper a oligomerização de nemo, e, de identificar polipeptìdeos que modulam a oligomerização de nemo, e, uso de uma quantidade eficaz de uma composição
WO2011049350A2 (fr) *	2009-10-19	2011-04-28	한올바이오파마주식회사	Polypeptide modifié du récepteur 1 du facteur humain de nécrose tumorale ou son fragment, et méthode de préparation associée
CN102399819B (zh) *	2011-08-24	2013-06-19	西北农林科技大学	一种质粒型腺病毒载体pAd-NRIP1及其构建方法
DE102011115480A1 (de) *	2011-10-06	2013-04-11	Biostep Gmbh	Substrat und Vorrichtung zur Chemilumineszenzdetektion
WO2016094846A1 (fr)	2014-12-11	2016-06-16	President And Fellows Of Harvard College	Inhibiteurs de nécrose cellulaire et procédés associés

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IL73883A (en) *	1984-12-20	1990-12-23	Yeda Res & Dev	Monoclonal antibodies against tnf-alpha,hybridomas producing them and method for the purification of tnf-alpha
IL94039A (en) *	1989-08-06	2006-09-05	Yeda Res & Dev	Antibodies to tbp - 1 and their use
ES2072330T5 (es) *	1989-05-18	2013-06-24	Yeda Research And Development Co., Ltd.	Proteínas de unión II al Factor de Necrosis Tumoral, su purificación y anticuerpos frente a los mismos
JP3860608B2 (ja)	1995-02-22	2006-12-20	イエダリサーチアンドディベロップメントカンパニーリミテッド	調節タンパク質のモジュレーター
US5674734A (en) *	1995-05-18	1997-10-07	President And Fellows Of Harvard College	Cell death protein
AU7457796A (en)	1995-10-23	1997-05-15	Tularik Inc.	Rip: novel human protein involved in tumor necrosis factor signal transduction, and screening assays
EP0914338A2 (fr)	1996-05-29	1999-05-12	Genzyme Corporation	Genes regulateurs de la croissance cellulaire

1998
- 1998-09-01 IL IL12602498A patent/IL126024A0/xx unknown
1999
- 1999-03-18 PT PT99910646T patent/PT1062336E/pt unknown
- 1999-03-18 HU HU0101612A patent/HUP0101612A3/hu unknown
- 1999-03-18 AT AT99910646T patent/ATE318310T1/de not_active IP Right Cessation
- 1999-03-18 BR BR9909659-5A patent/BR9909659A/pt not_active Application Discontinuation
- 1999-03-18 JP JP2000536855A patent/JP4351389B2/ja not_active Expired - Fee Related
- 1999-03-18 EA EA200000961A patent/EA004062B1/ru unknown
- 1999-03-18 CA CA002323637A patent/CA2323637A1/fr not_active Abandoned
- 1999-03-18 NZ NZ52556699A patent/NZ525566A/xx unknown
- 1999-03-18 KR KR1020057019204A patent/KR100748293B1/ko not_active Expired - Fee Related
- 1999-03-18 EE EEP200000538A patent/EE200000538A/xx unknown
- 1999-03-18 US US09/646,403 patent/US6734174B1/en not_active Expired - Fee Related
- 1999-03-18 NZ NZ506776A patent/NZ506776A/xx unknown
- 1999-03-18 DK DK99910646T patent/DK1062336T3/da active
- 1999-03-18 SK SK1376-2000A patent/SK285804B6/sk not_active IP Right Cessation
- 1999-03-18 CA CA002625284A patent/CA2625284A1/fr not_active Abandoned
- 1999-03-18 EP EP99910646A patent/EP1062336B1/fr not_active Expired - Lifetime
- 1999-03-18 PL PL343262A patent/PL200763B1/pl not_active IP Right Cessation
- 1999-03-18 DE DE69929958T patent/DE69929958T2/de not_active Expired - Fee Related
- 1999-03-18 ES ES99910646T patent/ES2258838T3/es not_active Expired - Lifetime
- 1999-03-18 AU AU29545/99A patent/AU760900B2/en not_active Ceased
- 1999-03-18 WO PCT/IL1999/000158 patent/WO1999047672A1/fr not_active Ceased
- 1999-03-18 CN CNB998041513A patent/CN1232641C/zh not_active Expired - Fee Related
2000
- 2000-09-14 BG BG104769A patent/BG64990B1/bg unknown
- 2000-09-18 NO NO20004649A patent/NO327854B1/no not_active IP Right Cessation
2006
- 2006-05-09 BG BG109537A patent/BG65684B1/bg unknown

Also Published As

Publication number	Publication date
ATE318310T1 (de)	2006-03-15
BG64990B1 (bg)	2006-11-30
PL343262A1 (en)	2001-07-30
JP2002506644A (ja)	2002-03-05
NO20004649D0 (no)	2000-09-18
BG65684B1 (bg)	2009-06-30
CA2323637A1 (fr)	1999-09-23
BG109537A (en)	2007-11-30
DE69929958T2 (de)	2006-11-23
DK1062336T3 (da)	2006-05-29
WO1999047672A1 (fr)	1999-09-23
CA2625284A1 (fr)	1999-09-23
ES2258838T3 (es)	2006-09-01
SK13762000A3 (sk)	2001-03-12
EP1062336A1 (fr)	2000-12-27
DE69929958D1 (de)	2006-04-27
KR20050107527A (ko)	2005-11-11
SK285804B6 (sk)	2007-08-02
BG104769A (en)	2001-04-30
EA200000961A1 (ru)	2001-04-23
EA004062B1 (ru)	2003-12-25
CN1232641C (zh)	2005-12-21
PT1062336E (pt)	2006-05-31
AU760900B2 (en)	2003-05-22
KR100748293B1 (ko)	2007-08-09
CN1295614A (zh)	2001-05-16
EP1062336B1 (fr)	2006-02-22
PL200763B1 (pl)	2009-02-27
NZ525566A (en)	2004-12-24
HUP0101612A3 (en)	2005-03-29
IL126024A0 (en)	1999-05-09
HUP0101612A2 (hu)	2004-01-28
JP4351389B2 (ja)	2009-10-28
HK1034995A1 (en)	2001-11-09
AU2954599A (en)	1999-10-11
NO20004649L (no)	2000-10-30
US6734174B1 (en)	2004-05-11
EE200000538A (et)	2002-04-15
NZ506776A (en)	2003-08-29
BR9909659A (pt)	2000-11-21

Legal Events

Date	Code	Title	Description
2010-11-01	MM1K	Lapsed by not paying the annual fees

Publication	Publication Date	Title
US8236507B2 (en)	2012-08-07	Modulators of TNF receptor associated factor (TRAF), their preparation and use
US20090075889A1 (en)	2009-03-19	Iren protein, its preparation and use
EP1062336B1 (fr)	2006-02-22	Modulateurs de la fonction de recepteurs de la famille des recepteurs tnf/ngf
AU6634798A (en)	1998-10-12	Modulators of the function of receptors of the tnf/ngf receptor family
AU2003200969B2 (en)	2007-11-01	Modulators of the function of receptors of the TNF/NGF receptor family and other proteins
AU767924B2 (en)	2003-11-27	Modulators of TNF receptor associated factor (TRAF), their preparation and use
EP1454985A2 (fr)	2004-09-08	Modulateurs de récepteurs de la famille de récepteurs TNF/NGF
CN100557021C (zh)	2009-11-04	Tnf/ngf受体家族和其它蛋白质的受体的功能的调节剂
IL126428A (en)	2010-02-17	Modulators of tnf receptor associated factor (traf), their preparation and use
MXPA00009138A (en)	2002-06-05	Modulators of the function of receptors of the tnf/ngf receptor family and other proteins
CZ20003421A3 (cs)	2001-03-14	DNA sekvence kódující protein asociovaný s RIP, protein kódovaný touto sekvencí a způsoby jeho použití